The permit will enable patients and physicians residing in the State of New York to gain access to the Company’s miRview mets, miRview squamous, and miRview meso tests.
Rosetta Genomics is working to gain NYS DOH approval for the first of its second generation tests miRview mets2.
Rosetta Genomics president and CEO Kenneth Berlin said that these microRNA-based diagnostic products are now available to residents of all 50 US states including New York State.
"Receipt of this permit confirms that Rosetta’s CAP-accredited, CLIA-certified laboratory meets the strict requirements of New York State for quality-controlled, accurate and reliable clinical laboratory services," Berlin said.
"Rosetta Genomics has made considerable investment in the development of our proprietary microRNA technology platform, and we have a robust portfolio of diagnostic tests on the market, nearing commercial launch and in development and we look forward to provide the benefits of these powerful diagnostic products to a growing number of clinicians and patients."
